You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

914 Results
Document
Jan 2019
Document
Jan 2019
Document
Jan 2019
Document
Jan 2019
Document
Jan 2019
Document
Jan 2019
Document
Feb 2019
Document
Feb 2019
Document
Feb 2019
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative
Funding:
Exceptional Access Program
    daBRAfenib - For the adjuvant treatment of resected Stage III cutaneous melanoma according to clinical criteria
Exceptional Access Program
    trametinib - For the adjuvant treatment of resected Stage III cutaneous melanoma according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
daBRAFenib,
trametinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2021
Blog post
Working at CCO, I hear “cancer” every day. But when my doctor said to me, “I think you have cancer,” the word took on a very different meaning. I was...
Feb 2019

Pages